Chongqing Zhifei Biological Products Co (SZSE:300122) Research & Development: ¥917 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:300122 Chongqing Zhifei Biological Products Co Ltd SZSE:300122
65 GF Score
Price ¥13.04
GF Value ¥13.99
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Chongqing Zhifei Biological Products Co Research & Development?

Chongqing Zhifei Biological Products Co SZSE:300122 +1.64% 65 Research & Development is ¥917 Mil as of Mar. 2026. GuruFocus rates SZSE:300122 with a GF Score™ of 65/100 and a GF Value™ of ¥13.99 (Fairly Valued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Chongqing Zhifei Biological Products Co's Research & Development for the three months ended in Mar. 2026 was ¥214 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥917 Mil.

Chongqing Zhifei Biological Products Co  (SZSE:300122) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Chongqing Zhifei Biological Products Co Research & Development Related Terms

Chongqing Zhifei Biological Products Co Research & Development Historical Data

* Premium members only.

The historical data trend for Chongqing Zhifei Biological Products Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chongqing Zhifei Biological Products Co Research & Development Chart

Chongqing Zhifei Biological Products Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 552.63 854.16 968.47 1,021.08 932.30

Chongqing Zhifei Biological Products Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 229.36 189.70 249.64 263.60 213.68
SZSE:300122
65GF Score
Chongqing Zhifei Biological Products Co Ltd SZSE:300122
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chongqing Zhifei Biological Products Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥917 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥917 Mil mean?
Chongqing Zhifei Biological Products Co (SZSE:300122) has a Research & Development of ¥917 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Chongqing Zhifei Biological Products Co and its competitors.
Is Chongqing Zhifei Biological Products Co's Research & Development too high?
Chongqing Zhifei Biological Products Co's current Research & Development is ¥917 Mil. Overall, Chongqing Zhifei Biological Products Co has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chongqing Zhifei Biological Products Co's Research & Development compare to VRTX and REGN?
Chongqing Zhifei Biological Products Co's Research & Development of ¥917 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Chongqing Zhifei Biological Products Co and its competitors. Chongqing Zhifei Biological Products Co's current Research & Development is ¥917 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Zhifei Biological Products Co stock overvalued right now?
Based on GuruFocus' analysis, Chongqing Zhifei Biological Products Co (SZSE:300122) is currently considered Fairly Valued. The stock's GF Value™ is ¥13.99, compared to a current price of ¥13.04 — trading 6.8% below its estimated fair value. The current Research & Development is ¥917 Mil. Chongqing Zhifei Biological Products Co's overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Chongqing Zhifei Biological Products Co (SZSE:300122), the current Research & Development is ¥917 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chongqing Zhifei Biological Products Co (SZSE:300122) Overvalued in 2026?

Based on GuruFocus' analysis, Chongqing Zhifei Biological Products Co stock appears to be undervalued. The current stock price of ¥13.04 is trading 6.8% below its estimated GF Value™ of ¥13.99. GuruFocus considers Chongqing Zhifei Biological Products Co to be Fairly Valued.

Key valuation signals for SZSE:300122:

  • Research & Development: ¥917 Mil
  • GF Value™: ¥13.99 vs. price of ¥13.04 (6.8% below fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the SZSE:300122 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chongqing Zhifei Biological Products Co Business Description

Address No. 1, Qingyun Road, 50th Floor, Building T1, IFC Center, Jiangbei District, Chongqing, CHN, 400020
Chongqing Zhifei Biological Products Co Ltd is engaged in research and development, production, and sales of vaccines and biological products. The company's main products include bacterial vaccines for the prevention of meningitis and pneumonia-based bacteria, biological products for the prevention and treatment of tuberculosis, viral vaccines for the prevention of rabies virus, influenza virus, and other viruses, general drugs and other biological products, among others.
65GF Score

Get the complete analysis for SZSE:300122

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥13.04
Price
¥13.99
GF Value